Safety and Early Signs of Efficacy of IL12-L19L19.
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the safety, tolerability and early signs of efficacy
of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic
solid carcinomas and diffuse large B-cell lymphoma (DLBCL), after previous immune checkpoint
blockade therapy.
The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish
MTD, as recommended dose (RD).
The secondary objectives of the study are to assess early signs of efficacy, the
determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.